Literature DB >> 17643927

Immunomodulation by statins: inhibition of cholesterol vs. isoprenoid biosynthesis.

Hedwich F Kuipers1, Peter J van den Elsen.   

Abstract

Due to their ability to inhibit the synthesis of cholesterol, statins are widely used in medical practice and are the principal therapy for hypercholesterolemia. In addition, various findings suggest that statins also exert anti-inflammatory properties and may so play a role in modulating the immune system. Because of these properties, statins could provide a potential treatment for various chronic inflammatory diseases, including neuroinflammatory disorders such as multiple sclerosis. Here, we will review the effect of statins on the expression and function of a variety of immune relevant molecules and the underlying mechanisms that contribute to the immunomodulatory properties of statins. In this discussion we will also evaluate the effects of statins on central nervous system cells to emphasize the potential of these agents in the treatment of neuroinflammatory disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17643927     DOI: 10.1016/j.biopha.2007.06.005

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  14 in total

1.  The neuroprotective effect of two statins: simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer's disease in rats.

Authors:  Ana Carolina Tramontina; Krista Minéia Wartchow; Letícia Rodrigues; Regina Biasibetti; André Quincozes-Santos; Larissa Bobermin; Francine Tramontina; Carlos-Alberto Gonçalves
Journal:  J Neural Transm (Vienna)       Date:  2011-07-10       Impact factor: 3.575

2.  Statins inhibit monocyte chemotactic protein 1 expression in endometriosis.

Authors:  Hakan Cakmak; Murat Basar; Yasemin Seval-Celik; Kevin G Osteen; Antoni J Duleba; Hugh S Taylor; Charles J Lockwood; Aydin Arici
Journal:  Reprod Sci       Date:  2012-01-19       Impact factor: 3.060

Review 3.  Lipids in the cell: organisation regulates function.

Authors:  Ana L Santos; Giulio Preta
Journal:  Cell Mol Life Sci       Date:  2018-02-09       Impact factor: 9.261

4.  The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease.

Authors:  S Blankier; B W McCrindle; S Ito; R S M Yeung
Journal:  Clin Exp Immunol       Date:  2011-03-01       Impact factor: 4.330

Review 5.  3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases.

Authors:  Joshua Z Willey; Mitchell S V Elkind
Journal:  Arch Neurol       Date:  2010-09

6.  Atorvastatin Decreases Renal Menaquinone-4 Formation in C57BL/6 Male Mice.

Authors:  Stephanie G Harshman; M Kyla Shea; Xueyan Fu; Michael A Grusak; Donald Smith; Stefania Lamon-Fava; Athan Kuliopulos; Andrew Greenberg; Sarah L Booth
Journal:  J Nutr       Date:  2019-03-01       Impact factor: 4.798

Review 7.  Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy.

Authors:  Babafemi Taiwo; Luis Barcena; Randall Tressler
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

8.  [18F]fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation.

Authors:  Delphine L Chen; Timothy J Bedient; James Kozlowski; Daniel B Rosenbluth; Warren Isakow; Thomas W Ferkol; Betsy Thomas; Mark A Mintun; Daniel P Schuster; Michael J Walter
Journal:  Am J Respir Crit Care Med       Date:  2009-07-02       Impact factor: 21.405

9.  Statins impair CD1d-mediated antigen presentation through the inhibition of prenylation.

Authors:  Masood A Khan; Richard M Gallo; Gourapura J Renukaradhya; Wenjun Du; Jacquelyn Gervay-Hague; Randy R Brutkiewicz
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.